Skip to main content

Advertisement

Table 2 Effectiveness of adalimumab at week 12 in patients with ankylosing spondylitis by subgroup of enthesitis or peripheral arthritis or both

From: Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis

  No enthesitis
+ no arthritis
(n = 457)
Enthesitis
+ no arthritis
(n = 512)
Arthritis
+ no enthesitis
(n = 107)
Enthesitis
+ arthritis
(n = 174)
Pvaluea
  Median First quartile, third quartile [95% confidence interval]  
BASDAI, 0 to 10
Baseline 5.9
4.9, 6.9
6.4
5.4, 7.5
6.7
5.7, 7.7
6.6
5.7, 7.6
< 0.001
Week 12 2.1
0.8, 4.1
2.6
1.1, 5.1
3.1
1.5, 4.8
2.7
1.2, 5.0
 
Change from baseline to week12 -3.6
-4.8, -1.7
[-3.8 to -3.3]
-3.4
-4.9, -1.5
[-3.7 to -3.1]
-3.1
-5.0, -1.8
[-4.0 to -2.7]
-3.5
-4.9, -1.7
[-3.7 to -2.9]
0.813
BASFI, 0 to 10
Baseline 4.9
3.4, 6.7
5.7
4.0, 7.3
5.8
3.7, 7.0
6.0
4.3, 7.5
< 0.001
Week 12 2.2
1.0, 4.3
2.7
1.0, 5.1
3.1
1.4, 5.3
2.8
1.3, 5.3
 
Change from baseline to week12 -1.9
-3.6, -0.7
[-2.1 to -1.7]
-2.1
-3.8, -0.6
[-2.4 to -1.7]
-1.8
-3.2, -0.7
[-2.2 to -1.5]
-1.9
-3.7, -0.5
[-2.2 to -1.5]
0.828
Patient's Global Assessment of disease activity, 0- to 100-mm visual analog scale
Baseline 67
49, 80
71
53, 83
72
54, 81
72
53, 83
0.004
Week 12 21
8, 46
24
8, 52
25
11, 48
26
10, 52
 
Change from baseline to week12 -35
-58, -14
[-40 to -32]
-38
-59, -15
[-42 to -34]
-39
-61, -13
[-48 to -26]
-33
-57, -12
[-41 to -24]
0.806
C-reactive proteinb, mg/dL
Baseline 1.2
0.6, 2.5
1.2
0.5, 2.4
1.5
0.8,3.6
1.3
0.6, 3.4
0.448
Week 12 0.4
0.2, 0.8
0.4
0.2, 0.8
0.6
0.2, 1.5
0.4
0.1, 0.9
 
Change from baseline to week12 -0.7
-2.1, -0.1
[-0.9 to -0.6]
-0.8
-1.7, -0.2
[-1.0 to -0.7]
-1.4
-1.7, -0.1
[-1.0 to -0.4]
-0.7
-2.6, -0.1
[-1.3 to -0.4]
0.857
  1. aP values (two-sided) are based on Jonckheere-Terpstra tests for trends between subgroups without enthesitis and peripheral arthritis, with either enthesitis or peripheral arthritis, and with both. bReference value is 0.4 mg/dL. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index.